(19) World Intellectual Property **Organization**

International Bureau





(43) International Publication Date 18 December 2003 (18.12.2003)

PCT

(10) International Publication Number WO 2003/103614 A3

(51) International Patent Classification⁷: 38/18, 31/702, 31/683, 31/661, 31/6615 A61K 7/48,

(21) International Application Number:

PCT/IB2003/002216

(22) International Filing Date: 10 June 2003 (10.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

(71) Applicant and

MI2002A001280 11 June 2002 (11.06.2002) IT GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(72) Inventor: GHISALBERTI, Carlo [BR/BR]; Rua Luis Dias 85/61, Itaim-Bibi, CEP-0542-080 São Paulo, SP (BR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,

(88) Date of publication of the international search report: 21 October 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

(54) Title: COMPOSITIONS FOR THE TREATMENT OF EDEMATOUS-FIRBROSCLEROTIC PANNICULOPATHY

(57) Abstract: The invention relates to the use of angiogenic agents for the manufacture compositions for the treatment of cellulite, better defined by the term "edematousfibrosclerotic panniculopathy" to elicit the endothelial repair and/or the neovascularization of the cellulite-affected area and tissues. The invention also claims a method for treating cellulite which comprises the administration of an angiogenic agent, preferably selected from angiogenic phospholipids, hyaluronan oligosaccharides, peptide growth factors and combination thereof and, optionally, secondary angiogenic agents.

Inte __ inal Application No PCT/IB 03/02216

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K7/48 A61K38/18 A61K31/702 A61K31/683 A61K31/661

A61K31/6615

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{tabular}{ll} Minimum documentation searched (classification system followed by classification symbols) \\ IPC 7 & A61K \end{tabular}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
E	WO 03/068210 A (CESTARO BENVENUTO; HUNZA DI PISTOLESI ELVIRA & C (IT); PISTOLESI ELVI) 21 August 2003 (2003-08-21) claims 1-6; examples 1-7	1-6, 20-22, 25-29	
E	WO 03/103625 A (GHISALBERTI CARLO) 18 December 2003 (2003-12-18) the whole document	28	
X,P	WO 03/011873 A (SAMPALIS FOTINI; NEPTUNE TECHNOLOGIES & BIORESS (CA)) 13 February 2003 (2003-02-13) claims 1,45,47,51,52,54	1-6, 20-22, 25-29	
	-/		

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.		
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search	Date of mailing of the international search report		
23 January 2004	1 4. 07. 2004		
Name and mailing address of the ISA	Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 Nt 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Fischer, J.P.		

3

Inter all Application No
PCT/IB 03/02216

	JATION) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/17498 A (GHISALBERTI CARLO) 15 March 2001 (2001-03-15) page 2, line 20 - page 2, line 23; claims 1-4,6-10	1-6, 20-22, 25-29
	page 3, line 4 - page 4, line 25	
X	WO 00/45774 A (LEIGH MATTHEW LOUIS STEVE; LEIGH STEVEN (GB); THOMPSON CAROLINE MARY) 10 August 2000 (2000-08-10) the whole document	1-6, 20-22, 25-29
X,P	WO 02/098436 A (DI PIERRO FRANCESCO; INDENA SPA (IT)) 12 December 2002 (2002-12-12) the whole document	1,2,20, 21,25-29
(, P	PATENT ABSTRACTS OF JAPAN vol. 2003, no. 02, 5 February 2003 (2003-02-05) & JP 2002 293711 A (GENERAL TOPICS SRL), 9 October 2002 (2002-10-09) abstract	1,2,20, 21,25-29
	& DATABASE WPI Derwent Publications Ltd., London, GB; AN 2003-270789 abstract	
	WO 98/00101 A (PINOTTI ANISIO ; COSMETICOS NATURAL IND COM (BR); GUERRA FILHO SAMUEL) 8 January 1998 (1998-01-08) the whole document	1,2,20, 21,25, 28,29
(WO 87/01939 A (UNIV BOSTON ; ANGIO MEDICAL CORP (US)) 9 April 1987 (1987-04-09) the whole document	28
(DATABASE CAPLUS [Online] XP002267809 retrieved from STN Database accession no. 2000:252033 abstract & JP 2000 109409 A (KAO CORP.) 18 April 2000 (2000-04-18)	28
(EP 0 659 755 A (ROUSSEL UCLAF) 28 June 1995 (1995-06-28) the whole document	28
	WO 99/26632 A (STATENS SERUMINSTITUT; KROGFELT KAREN A (DK); COHEN PAUL S (US); LAUX) 3 June 1999 (1999-06-03) the whole document	28
į	-/	

Inte __ nal Application No PCT/IB 03/02216

		PC1/1B 0		
	uation) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.	
X	WO 01/12141 A (KAMIMURA AYAKO; MATSUOKA TAKAKO (JP); KYOWA HAKKO KOGYO KK (JP); TAKA) 22 February 2001 (2001-02-22) the whole document & EP 1 214 928 A 19 June 2002 (2002-06-19)		28	
X	WO 01/26617 A (GOLZ BERNER KARIN ; ZASTROW LEONHARD (MC); COTY BV (NL)) 19 April 2001 (2001-04-19) the whole document		28	
X	FR 2 785 805 A (LAVIPHARM LAB) 19 May 2000 (2000-05-19) the whole document		28	
X	WO 97/09989 A (LXR BIOTECHNOLOGY INC; TOMEL LOUIS DAVID (US); BATHURST IAN C (US); F) 20 March 1997 (1997-03-20) claims 1,45-48		28	
			1	

International application No. PCT/IB 03/02216

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
- Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 20-27 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. X No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
see annex
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 20-27 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Present claims 1-29 relate to an extremely large number of possible compounds and products. The definitions "angiogenic agents", "angiogenic phospholipids" "functionally equivalent" and "secondary angiogenic agents" do not represent a definition in structural terms and refer to an extremly large number of possible compounds.

Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds and products claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds defined in the claims and in the examples.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-6, 20-21,26-29 (partially)

use of angiogenic phospholipids and compositions containing angiogenic phospholipids for the treatment and/or prevention of edematous-fibrosclerotic panniculopathy

2. claims: 1-2,7-9,20-21,23,25-29

use of hyaluronan oligosaccharides and compositions containing hyaluronan oligosaccharides for the treatment and/or prevention of edematous-fibrosclerotic panniculopathy

3. claims: 1-2,10-16,20-21,24-29

use of peptide growth factors and/or their functionally equivalent and compositions containing them for the treatment and/or prevention of edematous-fibrosclerotic panniculopathy

Inter al Application No
PCT/IB 03/02216

						03/02216
	Patent document ed in search report		Publication date		Patent family member(s)	Publication date
WC	03068210	A	21-08-2003	IT WO	MI20020270 A1 03068210 A1	12-08-2003 21-08-2003
WC	03103625	A	18-12-2003	IT WO	MI20021281 A1 03103625 A2	11-12-2003 18-12-2003
WO	03011873	Α	13-02-2003	WO EP	03011873 A2 1417211 A2	13-02-2003 12-05-2004
WO	0117498	A	15-03-2001	IT AU AU BR CA CN EP WO WO JP	MI991894 A1 6720000 A 6720300 A 6720500 A 0013897 A 2384028 A1 1378441 T 1214048 A1 0118161 A2 0117374 A1 0117498 A1 2003508479 T	09-03-2001 10-04-2001 10-04-2001 10-04-2001 14-05-2002 15-03-2001 06-11-2002 19-06-2002 15-03-2001 15-03-2001 04-03-2003
WO	0045774	Α	10-08-2000	AT DE EP WO	230251 T 60001096 D1 1146844 A1 0045774 A1	15-01-2003 06-02-2003 24-10-2001 10-08-2000
WO	02098436	А	12-12-2002	IT CA CZ WO EP SK	MI20011182 A1 2449485 A1 20033293 A3 02098436 A1 1392335 A1 14852003 A3	05-12-2002 12-12-2002 14-04-2004 12-12-2002 03-03-2004 04-05-2004
JP	2002293711	Α	09-10-2002	ΙΤ	BS20010027 A1	23-09-2002
WO	9800101	A	08-01-1998	BR WO	9602919 A 9800101 A1	12-01-1999 08-01-1998
WO	8701939	A	09-04-1987	US AU DK EP FI HU JP NO WO US US ZA	4710490 A 6548886 A 276787 A 0240562 A1 872438 A 44176 A2 63502341 T 872267 A 8701939 A1 4888324 A 4769362 A	01-12-1987 24-04-1987 29-05-1987 14-10-1987 01-06-1987 29-02-1988 08-09-1988 29-05-1987 09-04-1987 19-12-1989 06-09-1988 24-06-1987
JP	2000109409	Α	18-04-2000	NONE		
EP	0659755	A	28-06-1995	FR AU AU CA	2714382 A1 687931 B2 8170994 A 2139014 A1	30-06-1995 05-03-1998 06-07-1995 28-06-1995

Interi al Application No
PCT/IB 03/02216

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0659755	А		EP JP US US ZA	0659755 A1 7206879 A 6133463 A 5985292 A 9410134 A	28-06-1995 08-08-1995 17-10-2000 16-11-1999 20-12-1995
WO 9926632	A	03-06-1999	AT AU CA DE DE WO DK EP ES JP NZ US	216585 T 747288 B2 1333799 A 2316340 A1 69805100 D1 69805100 T2 9926632 A1 1051180 T3 1051180 A1 2177089 T3 2001523723 T 505233 A 6165997 A	15-05-2002 16-05-2002 15-06-1999 03-06-1999 29-05-2002 05-12-2002 03-06-1999 19-08-2002 15-11-2000 01-12-2002 27-11-2001 26-07-2002 26-12-2000
WO 0112141	A	22-02-2001	AU CA EP WO	6595900 A 2380640 A1 1214928 A1 0112141 A1	13-03-2001 22-02-2001 19-06-2002 22-02-2001
EP 1214928	A	19-06-2002	AU CA EP WO	6595900 A 2380640 A1 1214928 A1 0112141 A1	13-03-2001 22-02-2001 19-06-2002 22-02-2001
WO 0126617	Α	19-04-2001	WO AU CA EP JP	0126617 A1 1750799 A 2386273 A1 1217984 A1 2003528036 T	19-04-2001 23-04-2001 19-04-2001 03-07-2002 24-09-2003
FR 2785805	Α	19-05-2000	FR FR	2785805 A1 2785806 A1	19-05-2000 19-05-2000
WO 9709989	Α	20-03-1997	AU CA CN EP JP WO US	7071896 A 2229435 A1 1200036 A 0850064 A1 11512439 T 9709989 A1 6004579 A	01-04-1997 20-03-1997 25-11-1998 01-07-1998 26-10-1999 20-03-1997 21-12-1999